Cartesian Therapeutics Inc (RNAC)

Currency in USD
8.875
+0.155(+1.78%)
Real-time Data·
RNAC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.6608.875
52 wk Range
5.60011.800
Key Statistics
Prev. Close
8.72
Open
8.7
Day's Range
8.66-8.875
52 wk Range
5.6-11.8
Volume
14.28K
Average Volume (3m)
262.17K
1-Year Change
-22.3535%
Book Value / Share
-4.26
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
RNAC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.571
Upside
+289.54%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cartesian Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.571
(+289.54% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy40.00+361.89%-MaintainMay 26, 2026
H.C. Wainwright
Buy25.00+188.68%30.00MaintainMay 12, 2026
BTIG
Buy44.00+408.08%-MaintainMar 09, 2026
Mizuho
Buy40.00+361.89%-MaintainMar 09, 2026
Cantor Fitzgerald
Buy16.00+84.76%-UpgradeMar 09, 2026

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
0.46 / -0.88
Revenue / Forecast
164K / 179.67K
EPS Revisions
Last 90 days

RNAC Income Statement

Compare RNAC to Peers and Sector

Metrics to compare
RNAC
Peers
Sector
Relationship
P/E Ratio
−1.7x−4.0x−0.4x
PEG Ratio
0.01−0.100.00
Price/Book
−2.1x2.0x2.6x
Price / LTM Sales
178.6x8.1x3.1x
Upside (Analyst Target)
347.2%293.0%48.4%
Fair Value Upside
Unlock11.0%6.5%Unlock

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.42M8.24%21.00M
Other Institutional Investors
7.61M25.90%66.02M
Public Companies & Retail Investors
19.35M65.86%167.87M
Total
29.38M100.00%254.88M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Squarepoint OPS LLC7.62%2,238,48619,419
Squarepoint Master Fund Limited7.42%2,178,65218,900

People Also Watch

99.82
EPAM
-1.70%
47.060
QURE
+4.28%
22.73
XE
+11.70%
31.160
CUE
+0.26%
7.975
CRMD
-2.03%

FAQ

What Is the Cartesian Therapeutics (RNAC) Stock Price Today?

The Cartesian Therapeutics stock price today is 8.875 USD.

What Stock Exchange Does Cartesian Therapeutics Trade On?

Cartesian Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Cartesian Therapeutics?

The stock symbol for Cartesian Therapeutics is "RNAC."

What Is the Cartesian Therapeutics Market Cap?

As of today, Cartesian Therapeutics market cap is 263.830M USD.

What Is Cartesian Therapeutics's Earnings Per Share (TTM)?

The Cartesian Therapeutics EPS (TTM) is -5.612.

When Is the Next Cartesian Therapeutics Earnings Date?

Cartesian Therapeutics will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is RNAC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Cartesian Therapeutics Stock Split?

Cartesian Therapeutics has split 1 times.

How Many Employees Does Cartesian Therapeutics Have?

Cartesian Therapeutics has 75 employees.

What is the current trading status of Cartesian Therapeutics (RNAC)?

As of Aug 14, 2026, Cartesian Therapeutics (RNAC) is trading at a price of 8.875 USD, with a previous close of 8.720 USD. The stock has fluctuated within a day range of 8.660 USD to 8.875 USD, while its 52-week range spans from 5.600 USD to 11.800 USD.

What Is Cartesian Therapeutics (RNAC) Price Target According to Analysts?

The average 12-month price target for Cartesian Therapeutics is 34.571 USD, with a high estimate of 44 USD and a low estimate of 16 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +289.54% Upside potential.

What Is the RNAC Premarket Price?

RNAC's last pre-market stock price is 8.670 USD. The pre-market share volume is 390.000, and the stock has decreased by -0.050, or -0.570%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.